Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Ptosis that Resolves with Application of an Ice Pack
BMJ 369:m1147, Chakraborty, A. & Jacob, J., 2020
Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis
JAMA Neurol 72:1170-1174, Peeler, C.E.,et al, 2015
Evidence Report: The Medical Treatment of Ocular Myasthenia (An Evidence-Based Review)
Neurol 68:2144-2149, Benatar,M. &Kaminski,H.J., 2007
Ocular Myasthenia Gravis Treatment: The Case Against Prednisone Therapy and Thymectomy
Arch Neurol 64:1790-1792,1794, Gilbert,M.E.,et al, 2007
Ocular Myasthenia: Diagnosis, Treatment and Pathogenesis
The Neurologist 12:231-239, Kusner,L.,et al, 2006
Development of Generalized Disease at 2 Years in Patients with Ocular Myasthenia Gravis
Arch Neurol 60:243-248, Kupersmith,M.J.,et al, 2003
Ocular Myasthenia Gravis:Response to Long Term Immunosuppressive Treatment
JNNP 62:156-162, Sommer,N.,et al, 1997
Penicillamine-induced Myasthenia Gravis Associated with Antibodies to Acetylcholine Receptor
Neurol 28:847-849, Russell,A.S.,et al, 1978